Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd

Link copied
Case Copied 78 min read

FEDERAL COURT OF AUSTRALIA

Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd [2017] FCA 285

File number: NSD 2149 of 2016
Judge: BURLEY J
Date of judgment: 21 March 2017
Catchwords:

PRACTICE AND PROCEDURE – application for preliminary discovery – whether prospective applicant held reasonable belief of its right to obtain relief for patent infringement – whether additional requirements of r 7.23(1) of the Federal Court Rules 2011 (Cth) were satisfied – whether discretion under r 7.23(2) should be exercised – application dismissed

EVIDENCE – whether evidence admissible pursuant to s 76 of the Evidence Act 1995 (Cth) – whether rules of evidence should be waived pursuant to s 190

Legislation:

Evidence Act 1995 (Cth) ss 76, 190

Federal Court of Australia Act 1976 (Cth) s 23

Federal Court Rules 2011 (Cth) rr 7.21, 7.23

Cases cited:

C7 Pty Ltd v Foxtel Management Pty Ltd [2001] FCA 1864

Dallas Buyers Club LLC v iiNet Limited [2015] FCA 317; (2015) 112 IPR 1

Dasreef Pty Limited v Hawchar [2011] HCA 21; (2011) 243 CLR 588

EBOS Group Pty Ltd v Team Medical Supplies Pty Ltd (No 3) [2012] FCA 48; (2012) 199 FCR 533

John Holland Services Pty Ltd v Terranora Group Management Pty Ltd  [2004] FCA 679

Jones v Dunkel [1959] HCA 8; (1959) 101 CLR 298

Makita (Australia) Pty Ltd v Sprowles [2001] NSWCS 305; (2001) 52 NSWLR 705

ObjectiVision Pty Ltd v Visionsearch Pty Ltd [2014] FCA 1087; (2014) 108 IPR 244

Optiver Australia Pty Ltd v Tibra Trading Pty Ltd [2007] FCA 1560; (2007) 163 FCR 554

Optiver Australia Pty Ltd v Tibra Trading Pty Ltd [2008] FCAFC 133; (2008) 169 FCR 435

Paxus Services Ltd v People Bank Pty Ltd [1990] FCA 723; (1990) 99 ALR 728

Reeve v Aqualast Pty Ltd [2012] FCA 679

Sabre Corporation Pty Ltd v Russ Kalvin’s Hair Care Company (1993) 46 FCR 428

Schmidt v Won [1998] 3 VR 435

St George Bank Ltd v Rabo Australia Ltd [2004] 211 ALR 147; (2004) 211 ALR 147

Valra Pty Ltd as Trustee for Abdul Rahim Valibhoy Family Trust v Mag Men Holdings Pty Ltd [2016] FCA 23; 110 ACSR 554

Date of hearing: 8 and 9 February 2017
Registry: New South Wales
Division: General Division
National Practice Area: Intellectual Property
Sub-area: Patents and associated statutes
Category: Catchwords
Number of paragraphs: 177
Counsel for the Prospective Applicants: Mr R C Macaw QC with Mr C Dimitriadis SC
and Ms C Cochrane
Solicitor for the Prospective Applicants: DLA Piper Australia
Counsel for the Prospective Respondent: Mr D K Catterns QC with Mr J S Cooke
and Mr D B Larish
Solicitor for the Prospective Respondent: Ashurst Australia

ORDERS

NSD 2149 of 2016
BETWEEN:

PFIZER IRELAND PHARMACEUTICALS

First Prospective Applicant

WYETH LLC

Second Prospective Applicant

PFIZER AUSTRALIA PTY LTD ACN 008 422 348

Third Prospective Applicant

AND:

SAMSUNG BIOEPIS AU PTY LTD ACN 611 890 094

Prospective Respondent

JUDGE:

BURLEY J

DATE OF…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2017] FCA 285
Decision Date

CaseChat Overview and Summary

Pfizer Ireland Pharmaceuticals sought preliminary discovery against Samsung Bioepis AU Pty Ltd for alleged patent infringement. The primary legal issue was whether Pfizer held a reasonable belief that it had a right to obtain relief for patent infringement. This hinged on Pfizer's ability to demonstrate that it reasonably believed Samsung Bioepis had relevant documents in its control and that inspecting these documents would aid in deciding whether to commence proceedings. The court also needed to determine if the evidence presented was admissible under the Evidence Act 1995 and if the rules of evidence should be waived. Pfizer argued that its belief was reasonable based on the similarity between its process and Samsung Bioepis's BRENZYS product, and that Samsung Bioepis likely had relevant documents. However, the court found that Pfizer's chain of inferences did not rise above speculation and that the evidence did not sufficiently establish a reasonable belief in its right to relief. The court dismissed the application and ordered Pfizer to pay Samsung Bioepis's costs.

Orders

Orders of the court

1. The application be dismissed.

2. The applicants pay the respondent’s costs.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

The issues for determination are:(1)whether the applicants have a reasonable belief that they have the right to obtain relief for patent infringement from SBA in accordance with FCR 7.23(1)(a);(2)whether the applicants have established that after making reasonable inquiries, they do not have sufficient information to decide whether to start proceedings to obtain relief within FCR 7.23(1)(b);(3)whether the applicants reasonably believe that SBA has, or is likely to have, in its control documents directly relevant to the right to obtain the relief and that inspection of the documents would assist in making the decision within FCR 7.23(1)(a); and(4)whether the Court is satisfied that an order for discovery of the kind sought should be given.2. BACKGROUND2.1 Technical Background A biological medicine (also known as a biological, biologic or a biopharmaceutical) is a medicine that contains one or more active substances made by a biological process or derived from a biological source rather than by chemical synthesis. Biological medicines are manufactured in cell culture and include vaccines, gene therapies, and recombinant therapeutic proteins. Recombinant therapeutic proteins are proteins made by genetically engineered living bacterial, animal or plant cells. Biological medicines can consist of relatively small molecules such as human insulin, or large and complex molecules such as mAbs and mAb-soluble receptor therapeutic products (also known as “cepts”). Compared with chemically synthesised small molecule medicines, biological medicines are larger in size and more complex. Cepts are large complex proteins with complicated three dimensional structures. They are inherently difficult to replicate and are sensitive to minor alterations in manufacturing processes and conditions, such as the host cell line, expression vector, master cell line, batch size, cell culture system, harvest process and purification process. Biological medicines are produced in living cells such as bacteria, yeast, insect cells and mammalian cells (host cells). This is made possible by the use of recombinant DNA technology. By using expression vectors or plasmids to introduce foreign DNA into host cells, the expression capabilities of the cells are “hijacked” to express the gene (and therefore the protein) of interest. Host cells containing the gene of interest are cultured in bioreactors and scaled up for industrial production, which, in cell culture, act as “cell factories” producing the protein. The parties agreed that the development of biological medicines can be conceptualised in four broad phases:(a)cell line development and creation of cell banks (including vector construction and engineering, transfection into the host cell, selection, formation of a stable host pool, and selection of clones);(b) upstream bioprocessing;(c) downstream bioprocessing; and(d) product characterisation and formulation. Cell line development and creation of cell banks (phase (a)) starts with the insertion of the gene of interest into an expression vector and the transfection of the recombinant vector or plasmid into the host cell. This is done in such a way that the host cell will synthesise useful amounts of the therapeutic protein.

Evidence

Evidence Before The Court

SBA objects to the relevant portions of Dr Ibarra’s evidence on the basis that it is bare assertion and is inadmissible pursuant to s 76 of the Evidence Act 1995 (Cth) (Evidence Act) and the principles expressed in Makita (Australia) Pty Ltd v Sprowles [2001] NSWCS 305; (2001) 52 NSWLR 705 (Makita) and that, if admitted, it should carry no weight. Dr Ibarra, SBA submits, has not identified the facts and assumptions upon which her opinion is based and no facts or assumptions or details of the Pfizer Process have otherwise been put into evidence. Further, Dr Ibarra does not explain how she has construed the claims of the patents. Pfizer submits first, that the evidence the subject of the objection was not opinion evidence at all but a statement of fact as to the presence of physical features of the process. Dr Ibarra’s intimate experience with the process as a result of her employment enabled her to state matters of fact. Secondly, that s 76 of the Evidence Act does not apply to applications of the present type because the task of the Court is not to determine questions of fact on a binding basis Optiver Australia Pty Ltd v Tibra Trading Pty Ltd [2007] FCA 1560; (2007) 163 FCR 554 (Optiver Australia) per Tamberlin J at [4]. Thirdly, that the Court should, in any event, dispense with the application of s 76 of the Evidence Act pursuant to the operation of s 190 of that Act; citing Dallas Buyers Club LLC v iiNet Limited [2015] FCA 317; (2015) 112 IPR 1 (Dallas Buyers Club) at [96] – [99] and Optiver Australia at [22]. Claim 1 of each of the three patents-in-suit is set out above. Each of these claims appears in patents going to highly technical subject matter. In my view, it is plain that matters of interpretation and opinion are required to form the view that a particular process falls within the claim. Taking the 632 patent as an example, integer 2 involves “growing cells in the cell culture at a reduced temperature, wherein the reduced temperature is in a range of 27.0˚C to less than 30.0˚C” involves an evaluation of the length of time at which the reduced temperature is sustained – is it the entire period of cell growth or something else? The same may be asked in respect of “reduced pH” in integer 3. Integer 4 plainly involves an evaluation, as senior counsel for Pfizer accepted. Dr Ibarra’s 8 February 2017 affidavit addressed this last point, but not integers 2 or 3. In relation to the 034 patent, integer 10 involves an evaluation and opinion as to what is within 20 – 80% of the “maximal possible viable cell density”. Integer 11 involves an evaluation as to what difference is sufficient to amount to “changing at least one of the culture conditions”. Dr Ibarra’s 8 February 2017 affidavit addressed integer 10 only. Patent cases are replete with examples of terms and patents being the subject of nuanced contention based on the opinion of experts in the field in the light of the common general knowledge as it existed as at the priority date.

Decision

Reasons for decision

Similarly, in relation to the 632 patent, the evidence to which I have referred does not, of itself, provide a basis that rises above speculation as to the presence of the integers in the BRENZYS Process.4.2 Conclusion in relation to FCR 7.23(1)(a) I turn now to consider whether, taken as a whole, the contentions presented by Pfizer establish the existence of a sufficient belief to entitle it to obtain relief within the principles set out above concerning FCR 7.23(1)(a). In this context I note the following matters by way of summary, drawing on my reasoning as expressed in [57] – [145] above. First, this is not a final hearing and I have not had the benefit of cross examination of witnesses. As I have noted in addressing the admissibility of Pfizer’s evidence, the relevant question concerns the grounds for the prospective applicant’s belief, and any consideration of the evidence does not involve making findings of fact. Secondly, I note that the mere fact that BRENZYS and ENBREL are biosimilar does not inform the question of what process is used to make either product. Thirdly, I consider the fact that it is agreed between the experts that the BRENZYS Process would satisfy the first three integers of claim one of each of the 034 and 036 patents and integer one of claim one of the 632 patent to be neutral. Those integers are present by reason of the fact that the protein of interest is etanercept. Fourthly, I regard the incentive and opportunity available to SBA to follow the method set out in the patents to be of little weight. Of itself, the existence of published patents can do little to incline the mind to the view that SBA knew of, regarded them to be advantageous and followed them. However, as I have noted above, I do accept that there is a likelihood that SBA was aware of the patents. The confidential evidence of Mr Lee suggests that literature searches would have been undertaken. Fifthly, the fact that Pfizer uses a serum free process does little to weigh the balance (or incline the mind) in favour of Pfizer, for the reasons given. Sixthly, the high point of Pfizer’s application involves a cascading series of inferences, each of which has the difficulties that I have set out in detail above. The chain of reasoning is, first, that the BRENZYS product has a peculiar level of similarity to the Pfizer product, a fact that can be inferred from the contents of the Cho article and the similarity between glycosylation profiles. Secondly, that the similarity between products enables the inference that the process to make each is similar. Thirdly that the Pfizer Process falls within the claims of the patents in issue. Fourthly, that because the Pfizer Process falls within the claims, the BRENZYS Process may likewise fall within the claims. I have examined each of these contentions in detail above (see [73] to [128] above). Each is confronted with significant difficulties. Taken together, as Pfizer urges, I am not satisfied that the evidence warrants the conclusion for which Pfizer contends. To the contrary, I am left with the firm view that this particular chain of inferences does not rise above speculation.

Ratio Decidendi

Legal Principle Established

In the present application, SBA led evidence to challenge the basis upon which Pfizer contended that the requisite objectively held belief arose. To a substantial extent, that evidence raised factual conflicts which it was not possible for me to determine on an application of this kind, there being no cross-examination, among other difficulties. Those difficulties were compounded by the fact that Dr Ibarra gave evidence in reply that generally took issue with the evidence of SBA’s witnesses, and then challenged only specific propositions which were advanced. That had the effect of leaving unclear precisely which matters were the subject of disagreement. 4. CONSIDERATION4.1 FCR 7.23(1)(a) Pfizer relies on six contentions which it submits, when considered cumulatively, give rise to the conclusion that it has the requisite belief within FCR 7.23(1)(a). I consider each separately below, and then cumulatively when I express my conclusions.First contention: some admitted integers Pfizer observes that it is common ground between the expert witnesses that the BRENZYS manufacturing process for etanercept would satisfy the first three integers of claim 1 of each of the 34 and 36 patents and integer 1 of claim 1 of the 632 patent. In my view this point does not go very far. The expert evidence agreed that every process for the manufacture of etanercept would satisfy these integers. Those integers are present by reason of the fact that the protein of interest is etanercept. Accordingly, I regard this factor, taken alone, as neutral.Second contention: advantage and opportunity Pifzer contends that in the development of the process for making BRENZYS, SBK had incentives, due to the advantages set out in the patents of the claimed processes and the widely recognized importance of those advantages, and the opportunity, given that the patents had been published, to adopt the processes used in the patents. As to the incentive for a party such as SBK to utilise the patents, Pfizer points to the evidence of Dr Ibarra who summarises the effect of the patents. In relation to the 034 and 036 patents, Dr Ibarra says that the process provides an improved system for large-scale production of polypeptides in cell culture, which involves the provision of amino acids, glutamine, asparagine, inorganic ions and concentrations that support relatively high levels of viable cell density and cell production that result in lower accumulation of metabolic waste products. These advantages are, it is said, reflected in the integers of the claims, which provide ranges desirable for media formulations. Professor Mahler’s evidence refers to each of the patents. Dr Ibarra in her evidence in reply does not specifically take issue with the Professor’s evidence concerning the effect of the patents. He understands the 034 patent to be concerned with phase (b), upstream processing and in particular “Media Prep” feeding into the large-scale bioreactors. In particular, he understands it to be primarily directed to batch and fed-batch processes with minimal feeds, although perfusion processes are not necessarily excluded. He points out that although the 034 patent teaches that a culture medium with “one, several or all” of the characteristics set out in integers 5 – 9 of claim 1 of the 034 patent may be used to optimise cell growth he observes that the patent does not teach that a culture medium with one or more of those characteristics will necessarily optimize the conditions of cell grown, viability and/or protein production (including etanercept). Professor Mahler developed this point by reference to an example given in the 034 patent of the use of a medium containing glutamine and having a medium characteristic selected from the group selected from the ranges set out in integers 5 – 9 of claim 1. He notes that the example given demonstrated that the medium having none of the characteristics identified within the ranges in the claim demonstrated a growth rate of relevant cells that was similar to that which did fall within the ranges.